INBX
Inhibrx Biosciences, Inc.
There isn't enough reported data to score INBX yet.
INBX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INBX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
INBX PE Valuation
INBX has no meaningful PE right now: it lost money over the past year.
INBX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INBX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
INBX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$8.88 | +$1.70 |
| Q1 2026 | -$8.39 | -107% |
| Q4 2025 | -$9.04 | -108% |
| Q3 2025 | -$10.02 | -108% |
| Q2 2025 | -$10.58 | -109% |
| Q1 2025 | $116.75 | +$122.10 |
| Q4 2024 | $118.11 | +$123.14 |
| Q3 2024 | $119.47 | +$123.72 |
INBX is still losing money, but less than at its worst: $8.88 per share over the past year, against $10.58 at its worst in mid-2025.
INBX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $1.3M | +1200% |
| Q4 2024 | $100K | -94% |
| Q2 2024 | $100K | +233% |
| Q4 2023 | $1.6M | +496% |
| Q3 2023 | $119K | -57% |
| Q2 2023 | $30K | -96% |
| Q1 2023 | $17K | -98% |
| Q4 2022 | $274K | -90% |
INBX's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -2107% | +158791 points |
| Q4 2024 | -49928% | -44525 points |
| Q2 2024 | -160898% | -23101 points |
| Q4 2023 | -5403% | +7553 points |
| Q3 2023 | -38510% | -27718 points |
| Q2 2023 | -137797% | -132931 points |
| Q1 2023 | -257447% | -254274 points |
| Q4 2022 | -12956% | -12271 points |
INBX's operating margin was −2107% last quarter, up 36403 points from the same quarter a year ago.
INBX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29.9M | +$36K |
| Q1 2026 | -$38M | -$2.1M |
| Q4 2025 | -$30.1M | +$13.6M |
| Q3 2025 | -$33.8M | -$3.3M |
| Q1 2025 | -$35.9M | +$28.3M |
| Q4 2024 | -$43.7M | +$16.5M |
| Q3 2024 | -$30.5M | +$24.5M |
| Q1 2024 | -$64.2M | -$37.2M |
INBX has burned cash in almost every quarter: −$132M over the past year, against −$140M the year before.
INBX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +84K shares |
| 1 year | +1.3% | +201K shares |
| 3 years | -64% | -28M shares |
| 5 years | -58% | -22M shares |
INBX has 16M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
INBX Net Leverage
INBX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INBX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.6 | Neutral |
| Stochastic | 22.7 | Neutral |
INBX's weekly RSI is 48 (neutral) and its Stochastic is 23 (neutral).
INBX PE vs Healthcare Sector
| Metric | INBX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INBX has no meaningful PE right now: it lost money over the past year.
INBX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $89.9 | 2.3% below |
| 20 week MA | $95.2 | 7.8% below |
| 50 week MA | $89.6 | 2.1% below |
| 100 week MA | $57.5 | 53% above |
INBX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 53% above its 100-week average.
INBX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $34.1 | $15.0 | -56% |
| 2025 | $15.0 | $80.2 | +434% |
| 2026 YTD | $80.2 | $87.8 | +9.4% |
INBX's yearly returns have swung widely, from +434% in 2025 to −56% in 2024. It's up 9.4% so far in 2026.